Skip to main content

Prior Head Injury Linked to Amyloid Deposition

SAN DIEGO — Patients with a history of head injury show significant increases in amyloid deposition in key parts of the brain, including the frontal cortex, a finding that further supports evidence linking head injury with dementia later in life.
"Our study found associations between prior head injury and increased amyloid deposition both globally and within the frontal cortex, including orbitofrontal, prefrontal, and superior frontal cortices," Andrea Schneider, MD, PhD, from Johns Hopkins University, Baltimore, Maryland, told Medscape Medical News.
"Our findings suggest that the frontal cortex may be particularly susceptible to the damaging effects of head injury."
The findings were presented here at the ANA 2017: 48th Annual Meeting of the American Neurological Association.
Head injury has been linked to dementia in previous epidemiologic studies, and while the mechanisms are not well understood, amyloid and tau depositions are speculated to be likely factors.
To take a closer look at the association, Dr Schneider and her colleagues identified 329 participants in the Atherosclerosis Risk and Communities (ARIC) study who underwent positron emission tomography assessing brain amyloid deposition between 2011 and 2013.
The patients had a mean age of 76 years, 57% were female, 43% were black, and 20% had a history of head injury, defined by self-report or hospitalization International Classification of Diseases, Ninth Revision, codes. Approximately one third (27%) of patients had mild cognitive impairment; however, patients with dementia were excluded.
Dr Schneider noted that patients with head injuries had sustained the injuries a mean of approximately 25 years earlier.
Those with a history of head injury showed elevated (greater than 1.2) standard uptake value ratios (SUVRs) indicating the presence of amyloid deposition, in global assessments (prevalence ratio [PR], 1.31; 95% confidence interval [CI], 1.07 - 1.60).
The elevated levels were specifically in the orbitofrontal cortex (PR, 1.24; 95% CI, 1.02 - 1.50), the prefrontal cortex (PR, 1.24; 95% CI, 1.03 - 1.49), and the superior frontal cortex (PR, 1.29; 95% CI, 1.06 - 1.56).
Meanwhile, there were no significant differences in the prevalence of elevated SUVR in the anterior cingulate, posterior cingulate, precuneus, lateral temporal, parietal, or occipital lobes (all P > .05).
"It was exciting to see that the frontal cortex was particularly associated with increased amyloid deposition among those with prior head injury," Dr Schneider said.
"We had also hypothesized that the posterior cingulate and precuneus areas would have elevated amyloid deposition, as these areas, along with the frontal cortex, have been shown to have early amyloid deposition in Alzheimer's dementia — but this hypothesis was not validated in our sample."
The findings add to ongoing speculation of a link between traumatic brain injury (TBI) and Alzheimer's disease, Dr Schneider added.
"Overall, our study is consistent with the conclusion that there is some overlap in areas with amyloid deposition in TBI and in early Alzheimer's pathology," she said.
Additional research is needed to better understand how amyloid deposition with head injury relates to dementia, Dr Schneider noted.
"Further work is needed to determine if this increased amyloid deposition contributes to dementia and cognitive decline following head injury in this population — this is an area of active research within the ARIC cohort study."

Insight on Mechanism

The study offers important insights on the possible mechanisms that could explain how TBI and amyloid relate, said Ramon Diaz-Arrastia, MD, PhD, presidential professor of neurology and attending neurologist at the Penn Presbyterian Medical Center Hospital of the University of Pennsylvania, in Philadelphia.

"It's been known for a long time that TBI, particularly more moderate or severe injury, is associated with an increased risk of dementia — approximately two- or threefold or so," he told Medscape Medical News.
"But little is known about the mechanism, and there is some [speculation] that TBI accelerates Alzheimer's disease pathology, and another view is that it accelerates perhaps another type of pathology, such as tau-related pathology or vascular dementia," he explained.
"So I think this is an important study because it is among the few that have looked at amyloid deposition in people with a history with TBI."
The location of the amyloid disposition that was identified "is also intriguing in that it is different from that expected with Alzheimer's disease," Dr Diaz-Arrastia said.
"The increased amyloid deposition is not in the canonical Alzheimer's disease regions but rather in these areas in the frontal lobes, which is important because the indications are that the features of dementia in people with TBI are not exactly like those we see with Alzheimer's disease."
The authors and Dr Diaz-Arrastia have disclosed no relevant financial relationships.
ANA 2017: 48th Annual Meeting of the American Neurological Association. Abstract M336WIP. Presented October 16, 2017.

Comments

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n